Recursion Pharmaceuticals (RXRX) Scheduled to Post Quarterly Earnings on Wednesday

Recursion Pharmaceuticals (NASDAQ:RXRX) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The firm’s revenue was up 30.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.38) earnings per share. On average, analysts expect Recursion Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Recursion Pharmaceuticals Price Performance

RXRX stock traded down $0.05 during midday trading on Tuesday, reaching $6.59. 1,696,199 shares of the stock were exchanged, compared to its average volume of 5,647,177. Recursion Pharmaceuticals has a 52 week low of $5.03 and a 52 week high of $15.74. The company has a fifty day moving average price of $6.61 and a 200 day moving average price of $7.64. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on RXRX shares. Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Finally, KeyCorp lowered their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.40.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total value of $81,502.64. Following the transaction, the director now owns 7,132,769 shares in the company, valued at $50,785,315.28. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,682 shares of company stock valued at $1,320,868 over the last quarter. Insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.